Across TCGA pan-cancer cohorts, GTF2IRD2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GTF2IRD2 data layer compared with 29 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher GTF2IRD2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated GTF2IRD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, STAD, and READ are the cancer types where GTF2IRD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	1.000	0.433	.008	34	view →
STAD	DFS	Median	II,III,IV	1.000	0.595	.020	10	view →
READ	OS	Median	All	0.281	0.823	<.001	9	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LUSC	OS	Median	All	0.005	0.762	<.001	6	view →
SKCM	DFS	Median	III,IV	0.119	0.654	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

Exploration

Same gene, other analysis: GTF2IRD2 tumor-vs-normal RNA expression · all GTF2IRD2 data types